SEC Company Response from Brickell Biotech, Inc. (FRTX) (CIK 0000819050) — Mar 15, 2021
Brickell Biotech, Inc. (FRTX) (CIK 0000819050)
Date: March 15, 2021 · CIK: 0000819050 · Accession: 0000819050-21-000042
AI Filing Summary & Sentiment
File numbers found in text: 333-254037
Letter
Re: Brickell Biotech, Inc.
Document
March 15, 2021
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3
File Number 333-254037
Ladies and Gentlemen:
Brickell Biotech, Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement on Form S-3 be accelerated so that it will become effective at 4:00 p.m. Eastern time on March 17, 2021, or as soon thereafter as practicable.
Please telephone the undersigned (305-582-4657) or Jonathan R. Zimmerman of Faegre Drinker Biddle & Reath LLP (612-766-8419) if you have any questions with respect to the foregoing.
Very truly yours,
BRICKELL BIOTECH, INC.
Show Raw Text
CORRESP
1
filename1.htm
Document
March 15, 2021
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Brickell Biotech, Inc.
Registration Statement on Form S-3
File Number 333-254037
Ladies and Gentlemen:
Brickell Biotech, Inc. (the “Company”) hereby requests that the effectiveness of the above-referenced registration statement on Form S-3 be accelerated so that it will become effective at 4:00 p.m. Eastern time on March 17, 2021, or as soon thereafter as practicable.
Please telephone the undersigned (305-582-4657) or Jonathan R. Zimmerman of Faegre Drinker Biddle & Reath LLP (612-766-8419) if you have any questions with respect to the foregoing.
Very truly yours,
BRICKELL BIOTECH, INC.
By: /s/ Andrew Sklawer
Name: Andrew Sklawer
Title: Chief Operating Officer